Noxopharm (ASX:NOX) share price edges lower after clinical trial update

The clinical-stage drug development company's shares have taken a tumble today

| More on:
Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX: NOX) share price is falling this afternoon. This comes after the company released an update about its DARRT-2 clinical trial.

At the time of writing, Noxopharm shares are swapping hands for 69 cents apiece, down 1.43%

What did Noxopharm announce?

Investors are selling Noxopharm shares after digesting the clinical-stage drug development company's latest release.

According to Noxopharm, it is on track to undertake a multi-national study for its flagship cancer-fighting drug, Veyonda. The drug is used in conjunction with radiotherapy.

Titled DARRT-2 (Direct and Abscopal Response to RadioTherapy), the phase 2 trial aims to treat late-stage prostate, breast and lung cancer patients for whom traditional treatment options such as chemotherapy and radiotherapy have failed.

The trial seeks to generate the phenomenon of the abscopal response in cancer patients. This is when a low dose of radiation not only shrinks a targeted tumour, but triggers an immune response that results in other tumours melting away. Noxopharm hopes the cancer cells could be eradicated within a matter of weeks.

The phase 2 trial is seeking to recruit 100 participants across 15 sites in Australia, the United States, France, and Hungary. International contract research organisation Parexel has been appointed to oversee the study.

Management commentary

Noxopharm CEO and managing director Dr Graham Kelly said:

The abscopal response is a highly attractive cancer treatment goal because it provides the opportunity for a major anti-cancer outcome from a generally safe and minimally invasive treatment. The challenge is that it is a very rare phenomenon that to date has proven difficult to reproduce on a consistent basis.

Recent research has pointed to a reason for this being the need to block a certain type of repair process called autophagy of mitochondrial DNA damaged by the radiation. Other research points to idronoxil, the active ingredient in Veyonda, blocking autophagy. It is the combination of that effect and the drug's known immuno-stimulatory effects, together with the earlier DARRT-1 trial data, that provides the confidence that we might have the ability to achieve consistently higher response rates to make DARRT a practical treatment option.

Noxopharm share price summary

Despite today's dip, Noxopharm shares have surged by more than 250% over the past 12 months. The company's share price reached a 52-week high of 99 cents in February, before treading lower from profit taking.

On valuation grounds, Noxopharm has a market capitalisation of roughly $201 million, with approximately 288 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »